PAPR1 inhibitors also show potential in many other cancers harboring deficiencies in DNA repair [21], and inhibition of other DNA repair genes is being evaluated to induce synthetic lethality, including PRKDC inhibition in MYC-overexpressing tumors [22]. The gene discussed is PRKDC; the disease is cancer.